Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in COVID-19 with Hyperinflammation
NCT05187793Phase 3Unknown
- Sponsor
- R-Pharm
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of olokizumab in coronavirus disease 2019 (COVID-19), sponsored by R-Pharm. Status: unknown.
02
Drugs
olokizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05187793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187793.